psalexa
logo

Neurofibromatoses Therapeutics - Pipeline Analysis 2018

Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: January 2018
Report Code: LS11248
Available Format:
Pages: 128

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Neurofibromatosis (NF) is an autosomal-dominant genetic disorder characterized by neurofibromas of the nerves and skin, café-au-lait spots on the skin (spots that look like coffee with milk), and developmental anomalies of the bones, muscles, and viscera. Usually there are two distinct types of NF namely; NF type 1 and NF type 2, also known as NF1 and NF2, respectively. Recently, a third type, known as schwannomatosis has been identified.

 

NEUROFIBROMATOSIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2018)

Neurofibromatosis Therapeutics

NF type 1 and NF type 2 are caused by defect on chromosome 17 and chromosome 22 respectively. Clinical diagnosis of NF1 includes blood tests, and a medical examination of the body by a physician. The presence of bilateral vestibular schwannomas (also known as acoustic neuroma) is the confirmatory diagnosis for NF type 2. AstraZeneca plc is in the process of Phase II stage of development by the selumetinib an orally active, small molecule for the treatment of NF.

Pipeline Analysis

The neurofibromatosis therapeutics pipeline has been analyzed based on different phases of development. The pipeline analysis of drugs by phases includes information about product description, research and development activities, and other development activities. The strategic development section provides information regarding designations, collaborations, licensing, grants, funding, technology and others.

As of January 2018, the neurofibromatosis therapeutics pipeline comprises of 25 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, and BioXcel Therapeutics Inc.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry